Menu visibility control

Video

Events

Startup Surgery

Most Recent

News

Top tech stats: Virgin’s business predictions, developers have their say and more

FinTech

London FinTech Aire raises $5m Series A from Sunstone Capital and White Star Capital

Sponsored

Tech Chats: EY’s Daniel Lyons on how tech is revolutionising transport

Press Releases

GreenKey Technologies and Red Box Recorders partner to launch integrated trading voice collaboration and compliance recording solution
Leading light in British HealthTech, Network Locum, rebrands to Lantum
SteelEye announces regulatory tech specialist Matt Smith as CEO

London-based biotech company Pulmocide raises $30.4m Series B

biotech
twitterlinkedinFacebookgoogle_plustwitterlinkedinFacebookgoogle_plus

Pulmocide, a biotech firm run by former GlaxoSmithKline scientists, has closed a $30.4m Series B.

The funding, which will be used to further develop its wholly-owned treatments for respiratory syncytial virus (RSV) and pulmonary aspergillosis, came from SV Life Sciences, Johnson & Johnson’s venture capital arm.

The London-based company also drew support from Touchstone Innovations and F-prime, the venture capital arm of Fidelity.

£195.6m in UK tech funding, the Taylor Review, WeWork’s huge Series G and more in The Week in Tech

“Respiratory infections are a significant cause of global morbidity and mortality with a high unmet medical need,” said company CEO Garth Rapeport.

“Pulmocide is developing bespoke inhaled medicines to provide effective and safe therapies for the treatment of RSV and pulmonary Aspergillosis. Our approach is to direct the drug to the site of the infection through an inhaler,” he explained.

The funding, the CEO added, will enable the firm to advance two of its ‘novel’ compounds through early clinical development.

“We are delighted by the interest we’ve received in this round and would like to thank our new and existing shareholders for their support and continued commitment to Pulmocide. We look forward to providing further pipeline updates as developments progress with our important programmes,” Rapeport added.

The news comes after the biotech firm secured $17m Series A round from four investors in November 2013.

Enter your email address to receive updates straight to your inbox

* indicates required
Send me news on...
twitterlinkedinFacebookgoogle_plustwitterlinkedinFacebookgoogle_plus

Editor's picks

startup tech laptop

Top tech stats: Virgin’s business predictions, developers have their say and more
posted on July 22, 2017

Aire Team picture June 2017_9

London FinTech Aire raises $5m Series A from Sunstone Capital and White Star Capital
posted on July 21, 2017

Tech Chats June - digital mobility

Tech Chats: EY’s Daniel Lyons on how tech is revolutionising transport
posted on July 21, 2017

mobile phone

London machine learning startup Sportr closes $350k Seed round
posted on July 21, 2017

The Week in Tech

A $170m tech fund, a drowning robot and more in The Week in Tech
posted on July 21, 2017

Graphcore founders Nigel Toon CEO (right) & Simon Knowles CTO (left)

Bristol-based Graphcore raises $30m from backers including DeepMind co-founder and Atomico
posted on July 20, 2017